GUERBET Aktie

>GUERBET Performance

1 Woche: +4,3%

1 Monat: -31,5%

3 Monate: -37,8%

6 Monate: -34,9%

1 Jahr: -56,5%

laufendes Jahr: -37,5%

>GUERBET Aktie

Name:

GUERBET SA INH. EO 1

Land:

Frankreich

Sektor:

Gesundheit

ISIN/ Wkn:

FR0000032526 / 870481

Symbol/ Ticker:

4G8 (Frankfurt)

Kürzel:

FRA:4G8, ETR:4G8, 4G8:GR

Index:

Webseite:

http://www.guerbet.com/

Profil:

Guerbet SA is a French pharmaceutical group specializing in the research, development, production, and sale of contrast media for medical imaging. Founded in 1926 by André Guerbet, the company traces its roots to the discovery of Lipiodol, the first..
>Volltext..

Marktkapitalisierung:

117.16 Mio. EUR

Unternehmenswert:

432.41 Mio. EUR

Umsatz:

800.2 Mio. EUR

EBITDA:

55.65 Mio. EUR

Nettogewinn:

-110.23 Mio. EUR

Gewinn je Aktie:

-8.74 EUR

Schulden:

445.5 Mio. EUR

Liquide Mittel:

117.55 Mio. EUR

Operativer Cashflow:

62.36 Mio. EUR

Bargeldquote:

0.48

Umsatzwachstum:

-6.5%

Gewinnwachstum:

-773.53%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Div. Historie:

01.07.24 - 0.5€
29.06.23 - 0.5€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

GUERBET

Letzte Datenerhebung:

06.04.26

>GUERBET Kennzahlen

Aktien/ Unternehmen:

Aktien: 12.62 Mio. St.

Frei handelbar: 42.53%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 2746

Umsatz/Mitarb.: 0.29 Mio. EUR

Analysten:

Analystenrating: Sell

Kursziel: 29.01%

Bewertung:

KGV: -

KGV lG: 10.74

KUV: 0.17

KBV: 0.43

PEG-Ratio: -

EV/EBITDA: 7.77

Rentabilität:

Bruttomarge: -7.11%

Gewinnmarge: -13.77%

Operative Marge: -12.15%

Managementeffizenz:

Gesamtkaprendite: -11.01%

Eigenkaprendite: -32.77%

>GUERBET Peer Group

Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege

>GUERBET Chart & Kurs - Stuttgart

>GUERBET News

11.03.26 - 17:48	GUERBET : Change in Guerbet′s Board of Directors. (GlobeNewswire EN)
	Change in Guerbet's Board of Directors...

11.03.26 - 17:48	GUERBET : 2025 full-year results. (GlobeNewswire EN)
	2025 full-year results...

20.02.26 - 17:24	New indication in pediatric patients, including term neonates for Guerbet′s half-dose GBCA, Elucirem™ (Gadopiclenol) Injection (PR Newswire)
	PRINCETON, N.J., Feb. 20, 2026 /PRNewswire/ -- Guerbet, a global specialist in contrast media and solutions for medical imaging, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved a labeling update for Elucirem™ (gadopiclenol) injection. The new......

05.02.26 - 17:48	Guerbet : 2025 revenue. (GlobeNewswire EN)
	2025 revenue...

28.01.26 - 17:48	Guerbet: Karim Boussebaa appointed Chief Executive Officer (GlobeNewswire EN)
	Karim Boussebaa Appointed Chief Executive Officer of Guerbet...

28.01.26 - 09:24	Corporate News: Guerbet (EQS)
	Neue Indikation bei Kindern ab Geburt für Guerbets halbe Dosis GBCA, Elucirem™ (Gadopiclenol), von der Europäischen Kommission zugelassen...

27.01.26 - 18:09	Corporate News: Guerbet (EQS)
	New indication in children from birth for Guerbet’s half-dose GBCA, Elucirem™ (Gadopiclenol) approved by European Commission...

27.01.26 - 18:03	New indication in children from birth for Guerbet′s half-dose GBCA, Elucirem™ (Gadopiclenol) approved by European Commission (PR Newswire)
	VILLEPINTE, France, Jan. 27, 2026 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a global specialist in contrast media and solutions for medical imaging, is delighted to announce the approval by European Commission of a new indication in children from birth for its macrocyclic......

19.12.25 - 08:48	Guerbet: Appointment of Mr. François Convenant as Senior Vice President of Interventional Radiology and his entry into the Executive Committee (GlobeNewswire EN)
	Guerbet announces the appointment of Mr. François Convenant as Senior Vice President of Interventional Radiology and his entry into the Executive Committee...

03.12.25 - 11:42	Guerbet: Gewinnwarnung nach FDA-Inspektion lässt Aktie einbrechen (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

02.12.25 - 17:48	GUERBET : Adjustment of 2025 financial targets. (GlobeNewswire EN)
	Adjustment of 2025 financial targets...

19.11.25 - 13:51	GUERBET : Financial agenda for 2026 (GlobeNewswire EN)
	Financial agenda for 2026...

23.10.25 - 17:48	Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025. (GlobeNewswire EN)
	Revenue at September 30, 2025...

24.09.25 - 17:48	Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on a like-for-like basis, mainly due to the decline in activity in France (GlobeNewswire EN)
	H1 2025 results...

22.09.25 - 17:48	Guerbet : Change in General Management (GlobeNewswire EN)
	Change in General Management...

15.09.25 - 17:54	Guerbet : Adjustment of 2025 full-year financial targets (GlobeNewswire EN)
	Adjustment of 2025 full-year financial targets...

24.07.25 - 17:48	Guerbet : H1 2025 revenue (GlobeNewswire EN)
	H1 2025 revenue...

26.05.25 - 08:45	Guerbet : Changes in the composition of the Guerbet board of directors. (GlobeNewswire EN)
	CHANGES IN THE COMPOSITION OF THE GUERBET BOARD OF DIRECTORS...

24.04.25 - 17:48	Guerbet: Q1 2025 revenue (GlobeNewswire EN)
	Q1 2025 revenue...

26.03.25 - 17:48	GUERBET : 2024 full-year results. (GlobeNewswire EN)
	2024 full-year results...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram